Compare

Essity AB/Skr ESSITY B

1D1W1M3M6MYTD1Y5YMAX

About Essity AB

Essity AB is a global hygiene and health company headquartered in Stockholm, Sweden. The company operates in the industry of hygiene and health products, providing essentials such as tissue paper, baby diapers, feminine care products, incontinence products, and medical solutions. With a wide range of offerings segmented into Personal Care, Consumer Tissue, and Professional Hygiene, Essity serves both consumer and business markets. The company traces its origins back to the hygiene business of SCA, from which it was spun off in 2017. Essity is known for its strong market positions in Europe and significant presence in Asia, Latin America, and North America, capitalizing on a diverse brand portfolio and scale of operations to maintain competitive advantage.
Ticker
Skr ESSITY B
Sector
Consumer Essentials
Primary listing
XSTO
Employees
36,000
Headquarters
Stockholm, Sweden
Website
www.essity.com

Essity AB Metrics

BasicAdvanced
kr 189B
17.14
kr 16.34
0.39
kr 8.75
3.13%

What the Analysts think about Essity AB

Analyst ratings (Buy, Hold, Sell) for Essity AB stock.
Analyst projections of the future price of Essity AB stock.

Bulls say / Bears say

Essity’s sales are showing signs of volume-led momentum: Q2 organic sales rose 0.3%, with volumes up 1.4% and growth in Health & Medical, Personal Care and Professional Hygiene. This suggests demand is holding up in several of its higher-growth areas. (Essity)
The planned acquisition of Kenvue’s Brazilian feminine-care business would deepen Essity’s position in an attractive market. The business recorded about BRL 800m in sales over the year to June 2026 and Essity says it was profitable, although the deal still needs approvals. (Essity)
Essity’s adjusted Q2 EBITA came in slightly ahead of analyst expectations despite higher cost inflation, showing some near-term earnings resilience. Management also expects its efficiency measures to have a greater effect in the second half of 2026. (ESM Magazine, Essity)
Input-cost inflation may outpace price increases in the near term: Goldman expects Q3 pricing gains to fall well short of rising unit costs. Essity’s adjusted EBITA margin had already eased to 13.4% in Q2 from 13.7% a year earlier. (Investing.com, Essity)
Consumer Tissue remains a clear weak spot: sales fell as both prices and volumes declined, while higher input costs had not yet been offset by price increases. Continued weakness here could weigh on group growth and margins. (Essity)
A potential sale of Consumer Tissue may not unlock value cleanly. UBS warns that operational links with other divisions could leave stranded costs and dissynergies, making a separation complex and its benefits slow to realise. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.

Essity AB Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Essity AB Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Essity AB

AllEURUSD
Funds
Fund name
Fund size
Skr ESSITY B weighting
iShares STOXX Europe 600 Personal & Household Goods€EXH7
€188M1.80%
Xtrackers MSCI Nordic£XDN0
€1.1B1.04%
HSBC MSCI Europe Islamic Screened£HIPS
€144M0.51%
HSBC MSCI Europe Islamic Screened$HIEU
€144M0.51%
iShares MSCI Europe SRI€IESE
€3.2B0.46%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.